Alnylam Pharmaceuticals Submits New Drug Application for Experimental Acute Hepatic Porphyria Drug
Aymanjed / Pixabay

Alnylam Pharmaceuticals Submits New Drug Application for Experimental Acute Hepatic Porphyria Drug

According to a press release from Alnylam Pharmaceuticals, the Massachusetts-based biopharmaceutical company has completed the submission of its New Drug Application (NDA) for givosiran — its experimental acute hepatic porphyria…

Continue Reading Alnylam Pharmaceuticals Submits New Drug Application for Experimental Acute Hepatic Porphyria Drug
Orphazyme Preps to File European Marketing Application for Experimental Niemann-Pick disease Type C Drug
stevepb / Pixabay

Orphazyme Preps to File European Marketing Application for Experimental Niemann-Pick disease Type C Drug

According to a press release from Danish biopharmaceutical company Orphazyme, the Company intents to proceed with a marketing authorisation application (MAA) for its experimental Niemann-Pick disease type C treatment arimoclomol.…

Continue Reading Orphazyme Preps to File European Marketing Application for Experimental Niemann-Pick disease Type C Drug
Experimental Beta Thalassemia Drug Gains Temporary Short-Term Approval in Europe
Capri23auto / Pixabay

Experimental Beta Thalassemia Drug Gains Temporary Short-Term Approval in Europe

According to a publication from BNN Bloomberg, regulatory authorities in the European Commission recently granted conditional marketing authorization (CMA) to Zynteglo. Zynteglo is a gene therapy designed to treat beta…

Continue Reading Experimental Beta Thalassemia Drug Gains Temporary Short-Term Approval in Europe

Study Links IL-1 Cytokines to Increased Scarring in Systemic Scleroderma Patients

According to a publication from Scleroderma News, a study recently published in Clinical & Transitional Immunology suggests that certain cytokines (small proteins that play an important role in communication between…

Continue Reading Study Links IL-1 Cytokines to Increased Scarring in Systemic Scleroderma Patients
Orchard Therapeutics Acquires Global Licensing Agreement for Experimental Mucopolysaccharidosis Drug
source: pixabay.com

Orchard Therapeutics Acquires Global Licensing Agreement for Experimental Mucopolysaccharidosis Drug

According to a publication from Biospace, British clinical drug developer Orchard Therapeutics has secured global intellectual property rights to research, manufacture, and market a gene therapy program for the treatment…

Continue Reading Orchard Therapeutics Acquires Global Licensing Agreement for Experimental Mucopolysaccharidosis Drug
Bayer’s Aliqopa Receives Breakthrough Therapy Status for Marginal Zone Lymphoma
source: pixabay.com

Bayer’s Aliqopa Receives Breakthrough Therapy Status for Marginal Zone Lymphoma

According to a publication from Benzinga, the U.S. Food and Drug Administration has granted Breakthrough Therapy status to Bayer's relapsed follicular lymphoma drug Aliqopa (copanlisib) for the treatment of marginal…

Continue Reading Bayer’s Aliqopa Receives Breakthrough Therapy Status for Marginal Zone Lymphoma
NIH Grants Funding for Scientist’s Heparin-Induced Thrombocytopenia Biomarker Research
source: pixabay.com

NIH Grants Funding for Scientist’s Heparin-Induced Thrombocytopenia Biomarker Research

According to a publication on EurekAlert, the National Institutes of Health recently awarded Dr. Jason Karnes, PharmD, PhD (and assistant professor in the University of Arizona College of Pharmacy) with…

Continue Reading NIH Grants Funding for Scientist’s Heparin-Induced Thrombocytopenia Biomarker Research
Senator Cruz Encourages FDA to Expand Number of Conditions Covered by Parallel Track Policy
courtesy of US Gov't

Senator Cruz Encourages FDA to Expand Number of Conditions Covered by Parallel Track Policy

In a letter to Dr. Norman Sharpless, the acting commissioner of the Food and Drug Administration since April 5, Senator Ted Cruz encouraged the federal agency to expand the number…

Continue Reading Senator Cruz Encourages FDA to Expand Number of Conditions Covered by Parallel Track Policy
Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study
qimono / Pixabay

Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study

According to a publication from Oncology Nurse Advisor, a study of 109 patients with myeloproliferative neoplasms (certain types of blood cancers) found that mortality rates for younger patients were similar…

Continue Reading Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study
Study Suggests Brain Enzyme Might Form Tubes That Transport Huntington’s Disease Protein
https://pixabay.com/en/nerve-cell-neuron-brain-neurons-2213009/

Study Suggests Brain Enzyme Might Form Tubes That Transport Huntington’s Disease Protein

According to a publication from Laboratory Equipment, a new animal study of mice with simulated Huntington's disease suggests that a protein associated with the symptoms of Huntington's can form small,…

Continue Reading Study Suggests Brain Enzyme Might Form Tubes That Transport Huntington’s Disease Protein
GoFundMe for Sara Geurts, Model with Ehlers-Danlos Bedridden After New Diagnosis
https://pixabay.com/en/money-piggy-bank-coins-finance-2180338/

GoFundMe for Sara Geurts, Model with Ehlers-Danlos Bedridden After New Diagnosis

According to a publication from People, Sara Geurts, a 28-year-old model with Ehlers-Danlos syndrome, has been bedridden for several weeks due to complications linked to her condition. Geurts, a Minneapolis…

Continue Reading GoFundMe for Sara Geurts, Model with Ehlers-Danlos Bedridden After New Diagnosis
Positive Results at End of Phase 3 Trial of Candidate Tuberous Sclerosis Complex Drug – CBD
cbd123 / Pixabay

Positive Results at End of Phase 3 Trial of Candidate Tuberous Sclerosis Complex Drug – CBD

According to a press release from the British biotechnology company GW Pharmaceuticals, the company has reported successful results at the conclusion of its phase 3 trial of tuberous sclerosis complex…

Continue Reading Positive Results at End of Phase 3 Trial of Candidate Tuberous Sclerosis Complex Drug – CBD
England’s NHS Reaches Agreement for Coverage with SMA Drug Manufacturer Biogen
source: pixabay.com

England’s NHS Reaches Agreement for Coverage with SMA Drug Manufacturer Biogen

According to a publication from Express Digest, Britain's National Health Service (NHS) has finally reached an agreement with American biotechnology company Biogen Inc. over the price of Spinraza - a…

Continue Reading England’s NHS Reaches Agreement for Coverage with SMA Drug Manufacturer Biogen
FDA Approves Investigational New Drug Application for Experimental Fabry Disease Therapy
https://pixabay.com/en/thumbs-up-okay-good-well-done-2056022/

FDA Approves Investigational New Drug Application for Experimental Fabry Disease Therapy

According to a publication from Fabry Disease News, the U.S. Food and Drug Administration (FDA) has approved American biotechnology company Avrobio's Investigational New Drug (IND) application for experimental Fabry disease…

Continue Reading FDA Approves Investigational New Drug Application for Experimental Fabry Disease Therapy

NIH Reverses Decision, Allows Doctors to Speak to Federal Investigators About Sepsis Study Objections

According to the Wall Street Journal, the National Institutes of Health (NIH) has reversed its initial decision to prevent two of its researchers from meeting with federal investigators to comment…

Continue Reading NIH Reverses Decision, Allows Doctors to Speak to Federal Investigators About Sepsis Study Objections